Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

por Sam Lim, Matthew Baker, Vimal Derebail, Yashaar Chaichian, Mark Genovese, Panduranga Rao, Winn Chatham, Michael Bubb, Hooman Hajian, Oksana Gurtovaya, Uptal Patel, James Tumlin
Publicado 2020